The New York biotech company Cynvec gave the first indications it’s made progress on a $10 million funding round – raising $1.9 million of that goal, according to a recent regulatory filings.
The company is developing a vaccine designed to target ovarian cancer by boosting the body’s immune system and kill cancer cells. It’s currently in pre-clinical development with the treatment.
Company officials this week declined to discuss the round.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
New York University professor Dr. Daniel Meruelo developed the treatment, called CYN-101. The vaccine uses a bio-engineered version of the Sindbis virus, which naturally gets transmitted to humans by mosquitoes and causes symptoms like joint pain and a rash. But the bio-engineered version is said to have anti-cancer properties and is being used to develop oncology drug immunotherapies.
The company was founded in 2004, received its first capital at the end of 2006, and previously raised about $5 million, according to regulatory filings.
Photo: Screenshot via Cynvec